AI Article Synopsis
- This study aims to evaluate the effectiveness and safety of Shenmai injection (SMI) as a treatment for chronic heart failure (CHF).
- Researchers will conduct a comprehensive search of various databases for relevant randomized controlled trials and use RevMan 5.3 software for data analysis and synthesis.
- The final results will provide evidence on whether SMI is a viable and safe option for CHF treatment.
Article Abstract
Background: This study will assess the efficacy and safety of Shenmai injection (SMI) for the treatment of chronic heart failure (CHF).
Methods: The following electronic bibliographic databases will be searched from inception to the March 25, 2020 without language and publication time limitations: MEDLINE, PUBMED, Cochrane Library, Web of Science, Scopus, WANGFANG, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. All randomized controlled trials related to the SMI for patients with CHF will be included. All study selection, data extraction, and study quality will be carried out by 2 reviewers. Any disagreements will be solved by a third reviewer through discussion. RevMan 5.3 software will be used for data synthesis and data analysis.
Results: This study will summarize the present evidence of SMI for the treatment of patients with CHF.
Conclusion: The findings of this study will determine whether SMI is effective and safety for the treatment of CHF or not.
Study Registration Number: INPLASY202050029.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329011 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000020663 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!